Career Enhancement Program

职业提升计划

基本信息

  • 批准号:
    10709236
  • 负责人:
  • 金额:
    $ 8.52万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-19 至 2028-07-31
  • 项目状态:
    未结题

项目摘要

Career Enhancement Program SUMMARY/ABSTRACT The central goal of the Career Enhancement Program (CEP) is to use the resources at MD Anderson to train exceptional young investigators who will reduce the morbidity and mortality from ovarian cancer by making advances in the early detection, prevention, and treatment of this disease. To achieve this goal, the SPORE CEP will provide two awards, each of $50,000 annually for up to two years, funded from the SPORE and matching funds from MD Anderson. The intent of each CEP award is to prepare the selected scientists to become international leaders in academic research relevant to ovarian cancer. We will achieve this through focused recruitment of a diverse cadre of promising young investigators. We will work in partnership with awardees to generate individualized development plan and provide them with outstanding clinical and a laboratory mentors and a mentoring committee, formal course work, coaching in grant and paper writing, leadership training, attendance at national meetings, networking with ovarian cancer scholars and completing and publishing a translational ovarian cancer research program. Over the past two decades, the Ovarian Cancer SPORE CEP has developed the careers of 27 young investigators. In the first year of the original grant, three postdoctoral trainees received CEP awards, and of the 24 faculty members supported since 2000, all but two have remained in academic research and 13 are engaged predominantly in ovarian cancer research. Seventeen have achieved federal peer-reviewed funding and five additional awardees have received competitive foundation grants. Three awardees from our 2017-2021 funded cycle have received two Ovarian Cancer Research Alliance (OCRA) Awards, one CPRIT award, one R01, one R21, and one U01. Since the inception of the program in 1999, our CEP awardees have published over 1,100 peer-reviewed papers regarding ovarian cancer.
职业提升计划摘要/摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT C BAST其他文献

ROBERT C BAST的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT C BAST', 18)}}的其他基金

Developmental Research Program
发展研究计划
  • 批准号:
    10709235
  • 财政年份:
    2023
  • 资助金额:
    $ 8.52万
  • 项目类别:
The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer
SIK2 抑制剂 GRN-300 增强卵巢癌中 PARP 抑制剂的敏感性和细胞毒性 T 细胞功能
  • 批准号:
    10709229
  • 财政年份:
    2023
  • 资助金额:
    $ 8.52万
  • 项目类别:
The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer
德克萨斯大学 MD 安德森癌症中心 SPORE 在卵巢癌中的应用
  • 批准号:
    10709227
  • 财政年份:
    2023
  • 资助金额:
    $ 8.52万
  • 项目类别:
DIRAS3 disrupts K-RAS clustering and signaling, enhancing autophagy and response to autophagy inhibition
DIRAS3 破坏 K-RAS 聚类和信号传导,增强自噬和对自噬抑制的反应
  • 批准号:
    10707965
  • 财政年份:
    2022
  • 资助金额:
    $ 8.52万
  • 项目类别:
Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms
开发用于早期检测算法的新型卵巢癌生物标志物
  • 批准号:
    10410452
  • 财政年份:
    2020
  • 资助金额:
    $ 8.52万
  • 项目类别:
Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms
开发用于早期检测算法的新型卵巢癌生物标志物
  • 批准号:
    10226017
  • 财政年份:
    2020
  • 资助金额:
    $ 8.52万
  • 项目类别:
Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms
开发用于早期检测算法的新型卵巢癌生物标志物
  • 批准号:
    10670063
  • 财政年份:
    2020
  • 资助金额:
    $ 8.52万
  • 项目类别:
Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms
开发用于早期检测算法的新型卵巢癌生物标志物
  • 批准号:
    9916297
  • 财政年份:
    2020
  • 资助金额:
    $ 8.52万
  • 项目类别:
Project 4: SIK2 PROVIDES A NOVEL TARGET FOR OVARIAN CANCER THERAPY IN COMBINATION WITH PACLITAXEL AND INHIBITORS OF PARP
项目 4:SIK2 结合紫杉醇和 PARP 抑制剂为卵巢癌治疗提供新靶点
  • 批准号:
    10005298
  • 财政年份:
    2017
  • 资助金额:
    $ 8.52万
  • 项目类别:
U.T. M. D. Anderson Cancer Center SPORE in Ovarian Cancer
UT
  • 批准号:
    9356787
  • 财政年份:
    2017
  • 资助金额:
    $ 8.52万
  • 项目类别:

相似海外基金

EVALUATION OF IOWA CANCER REGISTRY DATA LINKAGE WITH AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) CANCERLINQ. POP 9/10/19 - 9/9/20.
评估爱荷华州癌症登记处与美国临床肿瘤学会 (ASCO) CANCERLINQ 的数据链接。
  • 批准号:
    10026959
  • 财政年份:
    2019
  • 资助金额:
    $ 8.52万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了